Key result
Disopyramide clearance shows no difference between patients with and without MI or HF.
Why the study?
Does the presence of myocardial infarction or congestive heart failure alter the pharmacokinetics of intravenous disopyramide?
Does the presence of myocardial infarction or congestive heart failure alter the pharmacokinetics of intravenous disopyramide?
The pharmacokinetics of intravenous disopyramide are not significantly altered by the presence of acute myocardial infarction or congestive heart failure, suggesting the standard dosage regimen is satisfactory.
Answers are grounded in this paper and cite their sources.
Supports unchanged disopyramide dosing in MI or HF; leaves open confirmation in prospective trials.
Total body clearance, half-life and volume of distribution of disopyramide (Norpace, Searle G.D.) was measured during a six to eight hour infusion to steady state in twenty four patients with either congestive heart failure or acute myocardial infarction and compared to eleven patients without these diseases. All patients were given a bolus injection of 150 mg disopyramide followed by a continuous infusion of 18-24 mg per hour. Serum concentration of disopyramide and its main dealkylated metabolite were determined by HPLC. The clearance in patients without myocardial infarction or congestive heart failure was 1.71 +/- 0.60 ml/min./kg (mean +/- S.D.), not significantly different from those who had either myocardial infarction, congestive heart failure or both. Half-life was 798 min. in patients without heart failure, not significantly different from the values in the other groups. The ratio between disopyramide and its metabolite varied between 3 to 10. Twenty-six % of the steady state serum concentrations of disopyramide were outside the recommended therapeutic range (2-5 micrograms/ml), but no adverse haemodynamic effects were observed in any of the patients. The suggested dosage regimen of disopyramide seems to result in a satisfactory response.
No takes yet. Share an insight, caveat, or question.
Bonde et al. (1985) studied Myocardial Infarction and Heart Failure (n=35). Disopyramide vs. Patients without myocardial infarction or heart failure was evaluated on Total body clearance of disopyramide (ml/min./kg). Disopyramide clearance in patients with myocardial infarction or heart failure was not significantly different from the 1.71 ml/min/kg observed in patients without these conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: